Immunotherapy has been established as an important area in the therapy of malignant diseases. Immunogenicity sufficient for immune recognition and subsequent elimination can be by-passed by tumors through altered and/or reduced expression levels of major histocompatibility complex class I (MHC I) molecules. Natural killer (NK) cells can eliminate tumor cells in a MHC I antigen presentation‐independent manner by an array of activating and inhibitory receptors, which are promising candidates for immunotherapy. Here we summarize the latest findings in recogniz-ing and regulating MHC I molecules that affect NK cell surveillance of glioblastoma cells.
CITATION STYLE
Burster, T., Gärtner, F., Bulach, C., Zhanapiya, A., Gihring, A., & Knippschild, U. (2021, March 1). Regulation of mhc i molecules in glioblastoma cells and the sensitizing of nk cells. Pharmaceuticals. MDPI AG. https://doi.org/10.3390/ph14030236
Mendeley helps you to discover research relevant for your work.